Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Linz – page 16

419 clinical trials in Linz, Austria across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Linz at a glance
419
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

419 trials in Linz

Open in trial search

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

Study of Olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation

Partial seizures

Not yet recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bhv-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Conjunctivitis allergic

Not yet recruiting

Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Allergy Therapeutics (UK) Limited

A Phase 3 Study of Once‑Daily Treprostinil Palmitil Inhalation Powder for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dnth103
  • Sponsor:Dianthus Therapeutics Inc.

Crohn's disease

Not yet recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.U.

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Adenocarcinoma pancreas

Not yet recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE
  • Sponsor:Revolution Medicines Inc.

Pancreatic carcinoma

Not yet recruiting

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Linz

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on various forms of cancer, including prostate cancer, colorectal cancer, and lung cancer. Studies are evaluating novel therapeutic approaches and combination treatments.

  • Metastatic cancer treatments
  • Immunotherapy combinations
  • Novel drug therapies

Particular emphasis on personalized treatment approaches and targeted therapies for specific cancer types.

02 Autoimmune Conditions

Research targeting inflammatory and autoimmune disorders, including Crohn's Disease, plaque psoriasis, and uveitis. Studies evaluate new biological treatments and combination therapies.

  • Inflammatory disease management
  • Novel biological agents
  • Treatment resistance solutions

Focus on improving disease control and patient outcomes through innovative therapeutic approaches.

03 Cardiovascular and Metabolic Studies

Trials investigating treatments for cardiovascular disease and obesity, with emphasis on preventive measures and innovative therapeutic solutions.

  • Cardiovascular risk reduction
  • Metabolic disorder management
  • Safety assessments

Research aimed at developing safer and more effective treatments for metabolic and cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.